The Alopecia Areata Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Alopecia Areata Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Alopecia Areata Market.
Some of the key takeaways from the Alopecia Areata Pipeline Report:
- Companies across the globe are diligently working toward developing novel Alopecia Areata treatment therapies with a considerable amount of success over the years.
- Alopecia Areata companies working in the treatment market are Concert Pharmaceutical, Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, Chipscreen Biosciences, Forte Biosciences, HCW Biologics, Reistone Biopharma Company, Suzhou Zelgen Biopharmaceuticals, and others, are developing therapies for the Alopecia Areata treatment
- Emerging Alopecia Areata therapies in the different phases of clinical trials are- CS 12192, FB-102, HCW 9302, ANB030, LP-0133, LH-8, SHR0302, Jaktinib, CTP-543, and others are expected to have a significant impact on the Alopecia Areata market in the coming years.
- Deuterium just completed a phase III trial for the oral treatment of alopecia areata, and if approved, it will overtake baricitinib as the second alopecia areata medication to receive FDA approval. Recently, Sun Pharma announced plans to pay $576 million to purchase Concert Pharmaceuticals, the company that developed the deuruxolitinib.
- In October 2021, A Multicenter, Open-Label, Extension Study to Evaluate the Long-Term Safety and Efficacy of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata was started by Concert Pharmaceuticals. The study’s main goals are to test CTP-543’s long-term safety as well as its effects on treating hair loss in adult patients with chronic, moderate to severe alopecia areata
- In May 2021, A trial titled “A Double-Blind, Randomized,Placebo-Controlled Study to Evaluate the Efficacy and Safety of CTP-543 in Adult Patients With Moderate to Severe Alopecia Areata” was started by Concert Pharmaceuticals. This was a multi-center Phase 3 research to assess the safety and efficacy of an experimental study drug in people (18 years and older) with 50% or more scalp hair loss. The drug is named CTP-543
- In July 2020, The oral Janus Kinase inhibitor CTP-543 from Concert Pharmaceutical has received Breakthrough Therapy Designation from the US Food and Drug Administration (FDA) for the treatment of adult patients with an ongoing condition of moderate to severe alopecia areata. Additionally, CTP-543 has been granted Fast Track status for the treatment of alopecia areata
Alopecia Areata Overview
Alopecia Areata (AA) is an autoimmune skin condition in which a weak immune system harms the hair follicles. The immune system attacks its own body as a result of this flawiness, affecting the growth of new hair follicles. Immune cells have been clearly seen moving in the hair bulbs of the hair follicle in biopsy results.
Get a Free Sample PDF Report to know more about Alopecia Areata Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/alopecia-areata-pipeline-insight
Emerging Alopecia Areata Drugs Under Different Phases of Clinical Development Include:
- CS 12192: Chipscreen Biosciences
- FB-102: Forte Biosciences
- HCW 9302: HCW Biologics
- Deuruxolitinib: Concert Pharmaceuticals
- EQ101: Equillium
- MAX 40070: Maxinovel Pharmaceuticals
- ANB030: AnaptysBio
- LP-0133: LEO Pharma
- LH-8: Legacy Healthcare
- SHR0302: Reistone Biopharma Company
- Jaktinib: Suzhou Zelgen Biopharmaceuticals
- CTP-543: Concert Pharmaceutical
Route of Administration
Alopecia Areata pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
Molecule Type
Products have been categorized under various Molecule types, such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
Alopecia Areata Pipeline Therapeutics Assessment
- Alopecia Areata Assessment by Product Type
- Alopecia Areata By Stage and Product Type
- Alopecia Areata Assessment by Route of Administration
- Alopecia Areata By Stage and Route of Administration
- Alopecia Areata Assessment by Molecule Type
- Alopecia Areata by Stage and Molecule Type
DelveInsight’s Alopecia Areata Report covers around 20+ products under different phases of clinical development like-
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Alopecia Areata product details are provided in the report. Download the Alopecia Areata pipeline report to learn more about the emerging Alopecia Areata therapies
Some of the key companies in the Alopecia Areata Therapeutics Market include:
Key companies developing therapies for Alopecia Areata are – Aclaris Therapeutics, Concert Pharmaceuticals, Pfizer, Bristol Myers Squibb, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Galderma, Regeneron Pharmaceuticals, Kythera Biopharmaceuticals, Cipla Ltd., Histogen, Allergan, Cassiopea S.p.A., Berg LLC, Follica, Inc., Stemson Therapeutics, RepliCel Life Sciences Inc., Kyocera Corporation, and others.
Alopecia Areata Pipeline Analysis:
The Alopecia Areata pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Alopecia Areata with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Alopecia Areata Treatment.
- Alopecia Areata key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Alopecia Areata Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Alopecia Areata market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Alopecia Areata drugs and therapies
Alopecia Areata Pipeline Market Drivers
- Increasing in the number of cases of alopecia areata, increasing Research and Development activities in Alopecia treatment are some of the important factors that are fueling the Alopecia Areata Market.
Alopecia Areata Pipeline Market Barriers
- However, lack of approved therapies to treat alopecia Areata, side effects associated with the current treatment options and other factors are creating obstacles in the Alopecia Areata Market growth.
Scope of Alopecia Areata Pipeline Drug Insight
- Coverage: Global
- Key Alopecia Areata Companies: Concert Pharmaceutical, Pfizer, Legacy Healthcare, AnaptysBio, Eli Lilly and Company, Incyte Corporation, Novartis, Bioniz, Rigel Pharmaceuticals, Arcutis Biotherapeutics, LEO Pharma, Arena Pharmaceuticals, HCW Biologics, Chipscreen Biosciences, Forte Biosciences, HCW Biologics, Reistone Biopharma Company, Suzhou Zelgen Biopharmaceuticals, and others
- Key Alopecia Areata Therapies: CS 12192, FB-102, HCW 9302, ANB030, LP-0133, LH-8, SHR0302, Jaktinib, CTP-543, and others
- Alopecia Areata Therapeutic Assessment: Alopecia Areata current marketed and Alopecia Areata emerging therapies
- Alopecia Areata Market Dynamics: Alopecia Areata market drivers and Alopecia Areata market barriers
Request for Sample PDF Report for Alopecia Areata Pipeline Assessment and clinical trials
Table of Contents
|
1 |
Alopecia Areata Report Introduction |
|
2 |
Alopecia Areata Executive Summary |
|
3 |
Alopecia Areata Overview |
|
4 |
Alopecia Areata- Analytical Perspective In-depth Commercial Assessment |
|
5 |
Alopecia Areata Pipeline Therapeutics |
|
6 |
Alopecia Areata Late Stage Products (Phase II/III) |
|
7 |
Alopecia Areata Mid Stage Products (Phase II) |
|
8 |
Alopecia Areata Early Stage Products (Phase I) |
|
9 |
Alopecia Areata Preclinical Stage Products |
|
10 |
Alopecia Areata Therapeutics Assessment |
|
11 |
Alopecia Areata Inactive Products |
|
12 |
Company-University Collaborations (Licensing/Partnering) Analysis |
|
13 |
Alopecia Areata Key Companies |
|
14 |
Alopecia Areata Key Products |
|
15 |
Alopecia Areata Unmet Needs |
|
16 |
Alopecia Areata Market Drivers and Barriers |
|
17 |
Alopecia Areata Future Perspectives and Conclusion |
|
18 |
Alopecia Areata Analyst Views |
|
19 |
Appendix |
|
20 |
About DelveInsight |
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services